IL271212A - שיטות לטיפול ביתר שומן בדם בחולים סכרתיים על ידי מתן מעכב pcsk9 - Google Patents

שיטות לטיפול ביתר שומן בדם בחולים סכרתיים על ידי מתן מעכב pcsk9

Info

Publication number
IL271212A
IL271212A IL271212A IL27121219A IL271212A IL 271212 A IL271212 A IL 271212A IL 271212 A IL271212 A IL 271212A IL 27121219 A IL27121219 A IL 27121219A IL 271212 A IL271212 A IL 271212A
Authority
IL
Israel
Prior art keywords
administering
methods
diabetic patients
pcsk9 inhibitor
treating hyperlipidemia
Prior art date
Application number
IL271212A
Other languages
English (en)
Other versions
IL271212B1 (he
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Priority claimed from PCT/IB2018/054182 external-priority patent/WO2018225041A1/en
Publication of IL271212A publication Critical patent/IL271212A/he
Publication of IL271212B1 publication Critical patent/IL271212B1/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21062—Subtilisin (3.4.21.62)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IL271212A 2017-06-09 2018-06-09 שיטות לטיפול ביתר שומן בדם בחולים סכרתיים על ידי מתן מעכב pcsk9 IL271212B1 (he)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762517672P 2017-06-09 2017-06-09
US201762532162P 2017-07-13 2017-07-13
EP18305565 2018-05-04
PCT/IB2018/054182 WO2018225041A1 (en) 2017-06-09 2018-06-09 Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor

Publications (2)

Publication Number Publication Date
IL271212A true IL271212A (he) 2020-01-30
IL271212B1 IL271212B1 (he) 2024-08-01

Family

ID=62815099

Family Applications (2)

Application Number Title Priority Date Filing Date
IL314423A IL314423A (he) 2017-06-09 2018-06-09 שיטות לטיפול ביתר שומן בדם בחולים סכרתיים על ידי מתן מעכב pcsk9
IL271212A IL271212B1 (he) 2017-06-09 2018-06-09 שיטות לטיפול ביתר שומן בדם בחולים סכרתיים על ידי מתן מעכב pcsk9

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL314423A IL314423A (he) 2017-06-09 2018-06-09 שיטות לטיפול ביתר שומן בדם בחולים סכרתיים על ידי מתן מעכב pcsk9

Country Status (9)

Country Link
EP (1) EP3634469A1 (he)
JP (2) JP2020522544A (he)
KR (1) KR20200026826A (he)
CN (1) CN110913889A (he)
AU (1) AU2018280567A1 (he)
CA (1) CA3066317A1 (he)
IL (2) IL314423A (he)
MX (1) MX2019014831A (he)
TW (2) TW202310872A (he)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3326648T3 (pl) 2011-01-28 2021-10-11 Sanofi Biotechnology Kompozycje farmaceutyczne zawierające ludzkie przeciwciała przeciwko PCSK9
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
CN113876956B (zh) * 2020-07-01 2023-07-04 陈敏 Pcsk9抑制剂在制备促进皮肤色素生成产品中的应用
CN114525258A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达pcsk9阻断物的多能干细胞或其衍生物及应用
CN115992138A (zh) * 2021-09-30 2023-04-21 北京安龙生物医药有限公司 用于治疗与pcsk9相关疾病的靶向寡核苷酸

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2015140079A1 (en) * 2014-03-17 2015-09-24 Sanofi Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
JP6912374B2 (ja) * 2014-07-16 2021-08-04 サノフィ・バイオテクノロジー 高コレステロール血症を有する高心血管リスク患者を処置するための方法
KR20240017117A (ko) * 2014-07-16 2024-02-06 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
EA201890519A1 (ru) * 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов

Also Published As

Publication number Publication date
KR20200026826A (ko) 2020-03-11
TW201904608A (zh) 2019-02-01
CA3066317A1 (en) 2018-12-13
RU2019144346A (ru) 2021-07-09
AU2018280567A1 (en) 2020-01-23
JP2020522544A (ja) 2020-07-30
JP2023123842A (ja) 2023-09-05
IL271212B1 (he) 2024-08-01
EP3634469A1 (en) 2020-04-15
RU2019144346A3 (he) 2021-10-13
MX2019014831A (es) 2020-02-13
IL314423A (he) 2024-09-01
CN110913889A (zh) 2020-03-24
TW202310872A (zh) 2023-03-16

Similar Documents

Publication Publication Date Title
IL271212A (he) שיטות לטיפול ביתר שומן בדם בחולים סכרתיים על ידי מתן מעכב pcsk9
IL259479B (he) טיפול בסרטן באמצעות 2-דאוקסי-2-פלואורו-l-פוקוז בשילוב עם מעכב נקודת בקרה
IL244995B (he) הרכב רוקחי המכיל מעכב pcsk9 בטיפול בהיפרליפידמיה
EP3368062A4 (en) METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
PL3169353T3 (pl) SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
IL261420A (he) שיטות לטיפול בלקוחות עם היפרליפידמיה על ידי הוספת חסם pcsk9 בשילוב עם חסם angpt3
LT3371165T (lt) Btk inhibitorius, naudojamas vėžiui gydyti
EP3313514A4 (en) POSITIONING DEVICE FOR USE IN THERAPEUTIC TREATMENT
WO2014160281A3 (en) Method of enhancing delivery of therapeutic compounds to the eye
EP3862000C0 (en) CHRONIC COUGH TREATMENT MEDICATION
HK1252514A1 (zh) 包含與抗體組合施予的ido抑制劑的腫瘤治療劑
LT3406258T (lt) Vaistas, skirtas podagros gydymui
EP3391052A4 (en) METHOD FOR PREVENTING OR TREATING HYPOGLYKEMIA BY ADMINISTERING A GPR119 AGONIST
MX2017007245A (es) Metodos de tratamiento de la fibrosis.
GB201511595D0 (en) Medical device for treating a vein
IL271456B (he) הרכב רוקחי המכיל מעכב pcsk9 לשימוש בטיפול בהיפרליפידמיה
PT3167881T (pt) Etamsilato administrado localmente como medicamento
UA86338U (ru) Способ лечения беременных с гестационным диабетом
GB201712192D0 (en) SmartDepo-(extended-release injections) a promising new drug treatment for addiction
IL250080B (he) שיטות לטיפול בחולים עם היפרכולסטרולמיה הטרוזיגוטית משפחתית
SG10201911565YA (en) Method for identifying personalized therapeutic strategies for patients affected with a cancer
SG10201400824YA (en) Therapeutic Methods And Compositions For Treating Diabetes Utilizing Diterpenoid Compounds
UA92214U (ru) Способ лечения диабетической полиневропатии у больных сахарным диабетом 2-го типа
PH12014000105A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds